全文获取类型
收费全文 | 197篇 |
免费 | 12篇 |
专业分类
儿科学 | 7篇 |
基础医学 | 34篇 |
口腔科学 | 3篇 |
临床医学 | 16篇 |
内科学 | 53篇 |
皮肤病学 | 15篇 |
神经病学 | 4篇 |
特种医学 | 36篇 |
外科学 | 10篇 |
综合类 | 4篇 |
预防医学 | 16篇 |
药学 | 2篇 |
中国医学 | 2篇 |
肿瘤学 | 7篇 |
出版年
2022年 | 1篇 |
2020年 | 1篇 |
2019年 | 2篇 |
2018年 | 6篇 |
2017年 | 5篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2014年 | 5篇 |
2013年 | 4篇 |
2012年 | 6篇 |
2011年 | 7篇 |
2010年 | 8篇 |
2009年 | 4篇 |
2008年 | 9篇 |
2007年 | 5篇 |
2006年 | 6篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 2篇 |
2002年 | 3篇 |
2001年 | 5篇 |
2000年 | 6篇 |
1999年 | 4篇 |
1998年 | 8篇 |
1997年 | 8篇 |
1996年 | 6篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1990年 | 3篇 |
1989年 | 6篇 |
1988年 | 7篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 7篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1975年 | 2篇 |
1961年 | 1篇 |
排序方式: 共有209条查询结果,搜索用时 9 毫秒
1.
2.
3.
4.
5.
Zhiburt EB 《Voprosy virusologii》2004,49(4):46-48
Inactivation or elimination of (possibly) contaminated viruses from a pool of prepared several hundreds or thousands of donor-blood samples are an obligatory stage in the donor-blood preparation process. Virus-inactivation is verified through contaminating the basic material with viruses. The quality control of blood preparations, according to the Russian compulsory regulations, must include the testing of ready blood-based drugs for a lack of antibodies to HIV, hepatitis C virus and hepatitis B virus by using the test systems, which could not be exactly designed for the above purpose. Therefore, the below tasks are vital for the Russian Blood Service: 1) cancellation of the norm (belonging to the regulations of the quality control of blood preparations) to test the blood preparations for a lack of antibodies to HIV, hepatitis C virus and to the surface antigen of hepatitis B virus because it is biologically inexpedient and has no analogues in the world practice; 2) introduction of the virus-inactivation methods into the practice of plasma processing; 3) establishment of a special center that would evaluate the efficiency of the virus-inactivation methods used by producers of blood-based preparations; and 4) introduction of the methods of genetic testing of HIV, hepatitis B and C viruses into monitoring the quality of donor-sera pools that are later used in preparations' manufacturing. 相似文献
6.
7.
We have recently found that antibodies to L-selectin, the homing receptor on neutrophils, are as effective as those to beta 2-integrin at blocking formyl peptide-stimulated aggregation. Therefore, we investigated the requirements for expression of L-selectin and beta 2- integrin on adjacent cells during aggregation. Fluorescence flow cytometry allowed characterization of aggregates on the basis of size and color, as well as antibody binding to these two adhesive molecules. Formyl peptide-stimulated aggregate formation was measured for individual populations fluorescently labeled red (LDS-751) or green (CD44-FITC), and interpopulation red-green cell conjugates. Blocking either the beta 2-integrin or L-selectin adhesive epitope with monoclonal antibody on individual cell populations resulted in an approximately 50% reduction in two-color aggregation as compared with that in unblocked samples. Shedding the L-selectin on a cell population by preincubation with complexes of lipopolysaccharide and its plasma membrane binding protein also decreased aggregation to a control population by approximately 50%. We examined the aggregation of neutrophils from patients genetically deficient in beta 2-integrin and clinically leukocyte adhesion deficient (LAD). LAD adhesion to normal neutrophils was dependent on the expression of L-selectin on LAD cells and beta 2-integrin on normal cells. Thus, the minimum requirement for adhesion between two mixed populations of neutrophils was that one population expressed the beta 2-integrin and the other expressed the L- selectin adhesive epitope. 相似文献
8.
9.
The contribution of von Willebrand factor (vWF)-platelet binding to platelet-collagen interaction was examined in vitro. The binding of vWF to platelets was mediated and regulated by ristocetin. Subthreshold concentrations of ristocetin (less than or equal to 1 mg/mL), insufficient to cause ristocetin-induced platelet aggregation (RIPA), were added to platelet-rich plasma (PRP) prior to the addition of collagen. The collagen-induced platelet aggregation (CIPA) was modified by ristocetin and the degree of alteration was dependent on the ristocetin concentration. Response as a function of ristocetin concentration was designated the Collagen-Platelet Aggregation Response (CoI-PAR). In normal PRP the CoI-PAR was a progressive inhibition followed by decreasing inhibition and then an enhanced response. The enhanced response occurred over a narrow range of ristocetin concentrations (0.8 to 1.0 mg/mL). In the absence of vWF (severe von Willebrand's disease, Type I, vWF less than 1%) the CoI-PAR was a progressive, eventually complete inhibition with no enhanced response (with ristocetin concentrations up to 3.0 mg/mL). With addition of vWF to this PRP an enhanced response was observed at a ristocetin concentration inversely proportional to the vWF level. PRP from a patient with severe Hemophilia A showed a response within the normal range. Subthreshold ristocetin did not cause plasma protein precipitation or platelet release of 3H-serotonin, nor induce micro platelet aggregate formation. Digestion of platelet membrane glycoproteins (GP(s] with chymotrypsin demonstrated that upon removal of GPI, RIPA was absent, CIPA retained and the CoI-PAR was progressive inhibition, with no enhancement. With removal of GPs I, II, and III, RIPA, CIPA, and the CoI-PAR were absent. A dose-response 125I-vWF- platelet binding occurred with increasing ristocetin concentrations which was unchanged by the addition of collagen. These results demonstrated that ristocetin-platelet association inhibited CIPA, and vWF-platelet binding enhanced platelet-collagen adhesion and platelet aggregation. The in vitro-enhanced CIPA represents a vWF-dependent aggregation of sufficient magnitude to overcome the inhibitory effect of ristocetin. These studies demonstrate an influential interaction of ristocetin, vWF, and collagen with the platelet membrane and imply an important hemostatic contribution of vWF-platelet binding in platelet- collagen interaction. 相似文献
10.